Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.36 |
| ▸ | PTGFR | P43088 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 4/20 | 0.35 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | GPR6 | P46095 | 2/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150028 | 0.90 | GCGR (0.39) | GCGRPDK1PDK2PDK3PDK4 | |
| SCHEMBL3170148 | 0.90 | PTGFR (0.39) | GCGRPDK1PDK2PDK3PDK4 | |
| SCHEMBL4146506 | 0.90 | GCGR (0.39) | GCGRPDK1PDK2PDK3PDK4 | |
| SCHEMBL4136944 | 0.90 | PDK1 (0.42) | GCGRPDK1PDK2PDK3PDK4 | |
| SCHEMBL4148816 | 0.89 | GCGR (0.38) | GCGRPDK1PDK2PDK3PDK4 | |
| SCHEMBL4140219 | 0.89 | GCGR (0.38) | GCGRPDK1PDK2PDK3PDK4 | |
| SCHEMBL13436115 | 0.88 | GCGR (0.38) | GCGRPDK1PDK2PDK3PDK4 | |
| SCHEMBL4146334 | 0.88 | CNR2 (0.38) | GCGRPDK1PDK2PDK3PDK4 | |
| SCHEMBL4147079 | 0.88 | KMT2A (0.39) | GCGRPDK1PDK2PDK3PDK4 | |
| SCHEMBL4138666 | 0.87 | GCGR (0.39) | GCGRPDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062396-A1 | Novel Haloalkoxy-Substituted Salicylic Anilides | NOVO NORDISK A/S (DK) | 2009-03-05 | — | — | US | claimed |
| EP-1888508-A2 | NOVEL HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2008-02-20 | — | — | EP | claimed |
| WO-2006125781-A2 | HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2006-11-30 | — | — | WO | claimed |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10772854-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200276140-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-09-03 | — | — | US | disclosed |
| US-10744103-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | MONTERESEARCH S.R.L. (IT) | 2019-10-03 | — | — | US | disclosed |
| US-20090062396-A1 | Novel Haloalkoxy-Substituted Salicylic Anilides | NOVO NORDISK A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| EP-1888508-A2 | NOVEL HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006125781-A2 | HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | GCGR 1865/4885PDK1 1128/4885PDK2 1106/4885 |
| US-10744103-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | GCGR 1865/4885PDK1 1128/4885PDK2 1106/4885 |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | GCGR 1824/4885PDK1 1135/4885PDK2 1116/4885 |
| US-20090062396-A1 | Novel Haloalkoxy-Substituted Salicylic Anilides | FABP4, HDHD5, HSPD1 | GCGR 1042/4885PDK1 1672/4885PDK2 2691/4885 |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | GCGR 1824/4885PDK1 1135/4885PDK2 1116/4885 |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | GCGR 1824/4885PDK1 1135/4885PDK2 1116/4885 |
| US-20200276140-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | GCGR 1824/4885PDK1 1135/4885PDK2 1116/4885 |
| US-10772854-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | GCGR 1721/4885PDK1 1159/4885PDK2 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.